JP2023548443A - Ｃｄ２８およびｐｄ－ｌ１を標的とする多特異性抗体ならびにその使用方法 - Google Patents

Ｃｄ２８およびｐｄ－ｌ１を標的とする多特異性抗体ならびにその使用方法 Download PDF

Info

Publication number
JP2023548443A
JP2023548443A JP2023551651A JP2023551651A JP2023548443A JP 2023548443 A JP2023548443 A JP 2023548443A JP 2023551651 A JP2023551651 A JP 2023551651A JP 2023551651 A JP2023551651 A JP 2023551651A JP 2023548443 A JP2023548443 A JP 2023548443A
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
light chain
chain polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023551651A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023548443A5 (https=
JPWO2022094299A5 (https=
Inventor
キャンベル，デイビッド
アール． ディライモンド，トーマス
Original Assignee
ジャナックス セラピューティクス，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジャナックス セラピューティクス，インク． filed Critical ジャナックス セラピューティクス，インク．
Publication of JP2023548443A publication Critical patent/JP2023548443A/ja
Publication of JP2023548443A5 publication Critical patent/JP2023548443A5/ja
Publication of JPWO2022094299A5 publication Critical patent/JPWO2022094299A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023551651A 2020-10-30 2021-10-29 Ｃｄ２８およびｐｄ－ｌ１を標的とする多特異性抗体ならびにその使用方法 Pending JP2023548443A (ja)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US202063107942P 2020-10-30 2020-10-30
US63/107,942 2020-10-30
US202063123329P 2020-12-09 2020-12-09
US202063123327P 2020-12-09 2020-12-09
US63/123,327 2020-12-09
US63/123,329 2020-12-09
US202163141268P 2021-01-25 2021-01-25
US63/141,268 2021-01-25
US202163187699P 2021-05-12 2021-05-12
US202163187719P 2021-05-12 2021-05-12
US202163187690P 2021-05-12 2021-05-12
US63/187,719 2021-05-12
US63/187,690 2021-05-12
US63/187,699 2021-05-12
US202163189843P 2021-05-18 2021-05-18
US63/189,843 2021-05-18
PCT/US2021/057384 WO2022094299A2 (en) 2020-10-30 2021-10-29 Multispecific antibodies for targeting cd28 and pd-l1 and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2023548443A true JP2023548443A (ja) 2023-11-16
JP2023548443A5 JP2023548443A5 (https=) 2024-11-07
JPWO2022094299A5 JPWO2022094299A5 (https=) 2024-11-07

Family

ID=81384468

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023551651A Pending JP2023548443A (ja) 2020-10-30 2021-10-29 Ｃｄ２８およびｐｄ－ｌ１を標的とする多特異性抗体ならびにその使用方法

Country Status (8)

Country Link
US (1) US20230406937A1 (https=)
EP (1) EP4237013A4 (https=)
JP (1) JP2023548443A (https=)
KR (1) KR20230136913A (https=)
AU (1) AU2021369835A1 (https=)
CA (1) CA3196726A1 (https=)
MX (1) MX2023005081A (https=)
WO (1) WO2022094299A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
JP2024518539A (ja) 2020-04-04 2024-05-01 ジャナックス セラピューティクス，インク． 抗体を標的とする腫瘍によって活性化されるｅｇｆｒおよびエフェクター細胞抗原に関する組成物および方法
EP4259177A4 (en) * 2020-12-08 2024-11-06 Janux Therapeutics, Inc. Peptide compositions and methods for anti-cd3 binding domains
JP2024511319A (ja) 2021-03-09 2024-03-13 ゼンコア インコーポレイテッド Ｃｄ３及びｃｌｄｎ６に結合するヘテロ二量体抗体
WO2024028386A1 (en) 2022-08-02 2024-02-08 Ose Immunotherapeutics Multifunctional molecule directed against cd28
CA3267921A1 (en) 2022-10-06 2024-04-11 Bicara Therapeutics Inc. MULTISPECIFIC PROTEINS AND ASSOCIATED PROCESSES
WO2024102723A2 (en) * 2022-11-10 2024-05-16 Janux Therapeutics, Inc. Antibodies targeting egfr and cd3 and uses thereof
EP4615879A2 (en) * 2022-11-11 2025-09-17 Janux Therapeutics, Inc. Compositions and uses of tumor activated antibodies targeting egfr and effector cell antigens
CN121532427A (zh) * 2023-05-18 2026-02-13 首尔大学校产学协力团 抗cd40l/抗cd28双特异性抗体及其用途
WO2025026356A1 (zh) * 2023-07-31 2025-02-06 百奥泰生物制药股份有限公司 靶向肿瘤相关抗原与cd28的双特异性抗体及其应用
WO2025090973A2 (en) * 2023-10-27 2025-05-01 Xencor, Inc. Anti-trop2 x anti-pdl1 x anti-cd28 antibodies
TW202528349A (zh) * 2023-11-03 2025-07-16 美商詹努克斯治療有限公司 用於靶向psma及cd28之抗體及其用途
TW202535942A (zh) * 2023-11-03 2025-09-16 美商詹努克斯治療有限公司 用於靶向cd28之抗體及其用途

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019009726A1 (en) * 2017-07-06 2019-01-10 Merus N.V. BINDING MOLECULES FOR MODULATING THE BIOLOGICAL ACTIVITY EXPRESSED BY A CELL
JP2019529499A (ja) * 2016-09-30 2019-10-17 ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ 組織指向性発現を用いた抗体ベースの遺伝子治療
JP2019532017A (ja) * 2016-07-14 2019-11-07 フレッド ハッチンソン キャンサー リサーチ センター がんを治療するための異なるエピトープ結合を示す複数の二重特異性結合ドメイン構築物
WO2020014098A1 (en) * 2018-07-09 2020-01-16 Shanghai Epimab Biotherapeutics Co., Ltd. Efficiently expressed egfr and pd-l1 bispecific binding proteins
WO2020127618A1 (en) * 2018-12-21 2020-06-25 F. Hoffmann-La Roche Ag Tumor-targeted agonistic cd28 antigen binding molecules
WO2020198009A1 (en) * 2019-03-22 2020-10-01 Regeneron Pharmaceuticals, Inc. EGFR x CD28 MULTISPECIFIC ANTIBODIES
JP2020529864A (ja) * 2017-06-25 2020-10-15 システィミューン， インク．Ｓｙｓｔｉｍｍｕｎｅ， Ｉｎｃ． 多重特異性抗体とその作製及び使用方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018520650A (ja) * 2015-05-21 2018-08-02 アリゲーター・バイオサイエンス・アーベー 新規のポリペプチド
EP3307778A1 (en) * 2015-06-12 2018-04-18 Bristol-Myers Squibb Company Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways
JP2022513495A (ja) * 2018-12-21 2022-02-08 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 腫瘍標的化スーパーアゴニストｃｄ２８抗原結合分子

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019532017A (ja) * 2016-07-14 2019-11-07 フレッド ハッチンソン キャンサー リサーチ センター がんを治療するための異なるエピトープ結合を示す複数の二重特異性結合ドメイン構築物
JP2019529499A (ja) * 2016-09-30 2019-10-17 ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ 組織指向性発現を用いた抗体ベースの遺伝子治療
JP2020529864A (ja) * 2017-06-25 2020-10-15 システィミューン， インク．Ｓｙｓｔｉｍｍｕｎｅ， Ｉｎｃ． 多重特異性抗体とその作製及び使用方法
WO2019009726A1 (en) * 2017-07-06 2019-01-10 Merus N.V. BINDING MOLECULES FOR MODULATING THE BIOLOGICAL ACTIVITY EXPRESSED BY A CELL
WO2020014098A1 (en) * 2018-07-09 2020-01-16 Shanghai Epimab Biotherapeutics Co., Ltd. Efficiently expressed egfr and pd-l1 bispecific binding proteins
WO2020127618A1 (en) * 2018-12-21 2020-06-25 F. Hoffmann-La Roche Ag Tumor-targeted agonistic cd28 antigen binding molecules
WO2020198009A1 (en) * 2019-03-22 2020-10-01 Regeneron Pharmaceuticals, Inc. EGFR x CD28 MULTISPECIFIC ANTIBODIES

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CORRENTI,C.E., ET AL.: ""Simultaneous multiple anteraction T-cell engaging (SMITE) bispecific antibodies overcome bispecific", LEUKEMIA, vol. 32, no. 5, JPN7025004504, May 2018 (2018-05-01), pages 1239 - 1243, ISSN: 0005833052 *

Also Published As

Publication number Publication date
EP4237013A2 (en) 2023-09-06
AU2021369835A9 (en) 2024-07-11
US20230406937A1 (en) 2023-12-21
KR20230136913A (ko) 2023-09-27
CA3196726A1 (en) 2022-05-05
WO2022094299A2 (en) 2022-05-05
AU2021369835A1 (en) 2023-06-01
MX2023005081A (es) 2023-06-15
WO2022094299A3 (en) 2022-09-29
EP4237013A4 (en) 2025-02-26

Similar Documents

Publication Publication Date Title
JP2023548443A (ja) Ｃｄ２８およびｐｄ－ｌ１を標的とする多特異性抗体ならびにその使用方法
IL262321B2 (en) Compositions and methods for selective protein expression
JP7850721B2 (ja) Ｐｓｍａおよびエフェクタ細胞抗原を標的とする腫瘍活性化抗体に関連する組成物ならびに方法
CN108064242A (zh) 抗gitr抗体和其使用方法
US12161724B2 (en) Compositions and methods related to tumor activated antibodies targeting EGFR and effector cell antigens
US12540183B2 (en) Anti-CD4 antibodies
US20240092931A1 (en) Antibodies targeting trop2 and cd3 and uses thereof
KR20220123652A (ko) 다가 제제를 이용하여 γδ T-세포 집단을 확장시키는 방법 및 이의 조성물
US20230357447A1 (en) Tumor activated multispecific antibodies for targeting cd28 and pd-l1 and methods of use thereof
CN117616137A (zh) 靶向egfr和cd3的抗体及其用途
US20250154278A1 (en) Optimized antibodies targeting trop2 and uses thereof
WO2023147331A1 (en) Bispecific molecule with tunable affinity to a targetted antigen
US20240043565A1 (en) Antibodies targeting psma and cd3 and uses thereof
CN120435318A (zh) 靶向egfr和cd3的抗体及其用途
CN117098562A (zh) 用于靶向cd28和pd-l1的多特异性抗体及其使用方法
US20260049137A1 (en) Optimized antibodies targeting cd3 and uses thereof
CN116997573A (zh) 靶向psma和cd3的抗体及其用途
US20230406955A1 (en) Antibodies targeting her2 and cd3 and uses thereof
TW202528349A (zh) 用於靶向psma及cd28之抗體及其用途
CN116529262A (zh) 靶向trop2和cd3的抗体及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241029

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241029

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251014

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260114

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260406